Baseline uric acid levels and steady-state favipiravir concentrations are associated with occurrence of hyperuricemia among COVID-19 patients

OBJECTIVES: Favipiravir is an antiviral that is being evaluated for the treatment of COVID-19. Use of favipiravir is associated with elevation of serum uric acid levels. Risk factors for the occurrence of hyperuricemia are unclear. METHODS: Specimens from COVID-19 patients who received 10 days of fa...

Descripción completa

Detalles Bibliográficos
Autores principales: Koseki, Takenao, Nakajima, Kazuki, Iwasaki, Hitoshi, Yamada, Shigeki, Takahashi, Kazuo, Doi, Yohei, Mizuno, Tomohiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8666105/
https://www.ncbi.nlm.nih.gov/pubmed/34910957
http://dx.doi.org/10.1016/j.ijid.2021.12.324

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8666105/
https://www.ncbi.nlm.nih.gov/pubmed/34910957
http://dx.doi.org/10.1016/j.ijid.2021.12.324

Ejemplares similares